We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

Back to rankings

171 hedge funds and large institutions have $877M invested in Ariad Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 30

17% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 48

10% more capital invested

Capital invested by funds: $801M → $877M (+$76.3M)

3% more funds holding

Funds holding: 166 → 171 (+5)

7% more call options, than puts

Call options by funds: $53.1M | Put options by funds: $49.5M

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
171
Holders Change
+5
Holders Change %
+3.01%
% of All Funds
4.94%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
36
Increased
56
Reduced
48
Closed
30
Calls
$53.1M
Puts
$49.5M
Net Calls
+$3.61M
Net Calls Change
+$16.2M

Top Buyers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
+$51.6M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$24.7M
3
Renaissance Technologies
Renaissance Technologies
New York
+$17.5M
4
Deutsche Bank
Deutsche Bank
Germany
+$7.73M
5
ARTA
A.R.T. Advisors
New York
+$4.43M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$28.7M
2
CCM
Camber Capital Management
Massachusetts
-$17.5M
3
Franklin Resources
Franklin Resources
California
-$16.7M
4
Barclays
Barclays
United Kingdom
-$14M
5
PC
PointState Capital
New York
-$12.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
76
DekaBank Deutsche Girozentrale
Germany
$891K +$38.9K +5,000 +5%
FSA
77
Franklin Street Advisors
North Carolina
$814K +$252K +32,400 +47%
CM
78
Corvex Management
New York
$806K -$4.87M -625,000 -86%
6CM
79
683 Capital Management
New York
$806K – – –
VOYA Investment Management
80
VOYA Investment Management
Georgia
$777K -$4.88K -627 -0.6%
UBS AM
81
UBS AM
Illinois
$751K +$31.2K +4,000 +4%
Wells Fargo
82
Wells Fargo
California
$707K +$229K +29,380 +50%
MIG
83
Mariner Investment Group
New York
$682K +$659K +84,600 New
N
84
Natixis
France
$592K +$572K +73,450 New
JG
85
Jefferies Group
New York
$588K +$159K +20,468 +39%
AI
86
Axiom Investors
Connecticut
$553K +$534K +68,600 New
RB
87
Rodgers Brothers
Pennsylvania
$537K – – –
BIM
88
BlackRock Investment Management
Delaware
$501K -$7.09K -910 -1%
AIG
89
American International Group
New York
$499K +$346K +44,419 +254%
TAM
90
Tocqueville Asset Management
New York
$463K +$331K +42,500 +283%
Citigroup
91
Citigroup
New York
$449K +$262K +33,621 +152%
Ohio Public Employees Retirement System (OPERS)
92
Ohio Public Employees Retirement System (OPERS)
Ohio
$447K -$81.6K -10,472 -16%
PA
93
Pinnacle Associates
New York
$435K +$421K +54,020 New
Nomura Asset Management
94
Nomura Asset Management
Japan
$403K +$389K +50,000 New
Commonwealth Equity Services
95
Commonwealth Equity Services
Massachusetts
$399K +$243K +31,262 +171%
WAM
96
Wolverine Asset Management
Illinois
$396K +$177K +22,766 +86%
T. Rowe Price Associates
97
T. Rowe Price Associates
Maryland
$383K – – –
Bank of Nova Scotia
98
Bank of Nova Scotia
Ontario, Canada
$379K +$366K +47,000 New
IRF
99
IBM Retirement Fund
New York
$373K -$204K -26,226 -36%
SGH
100
Schonfeld Group Holdings
New York
$344K +$333K +42,703 New
2 3
4
5 6

ARIA Hedge Fund Activity: Q1 2014 in Review

171 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q1 2014, worth a combined $877M — up 9.5% from $801M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ARIA positions and 30 closed out — a net gain of 6 holders — while 56 added to existing stakes and 48 trimmed.

The largest buyer was Slate Path Capital, opening a new position worth an estimated $51.6M. The largest seller was Fidelity Investments, cutting an estimated $28.7M.

  • 171 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q1 2014, up from 166 in Q4 2013.
  • Funds reported $877M of Ariad Pharmaceuticals Inc stock for Q1 2014, up 9.5% quarter-over-quarter.
  • 36 funds opened new Ariad Pharmaceuticals Inc positions in Q1 2014 and 30 closed out, a net change of +6 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q1 2014 was Slate Path Capital, an estimated $51.6M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q1 2014 was Fidelity Investments, an estimated $28.7M sold.

Based on aggregated 13F filings for Q1 2014.